Dorzolamide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dorzolamide: From Open-Angle Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Dorzolamide is a topical carbonic anhydrase inhibitor, originally used to lower eye pressure in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for primary hereditary glaucoma, but no clinical trials and no publications specific to this indication were found, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma; ocular hypertension (the New Zealand licence record does not state an approved indication) |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 (model prediction only) |
| New Zealand Market Status | ✗ Cancelled only (no currently valid licence) |
| Number of Authorizations | 1 (cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Dorzolamide is a carbonic anhydrase inhibitor. Its pharmacological targets include carbonic anhydrases 1, 7, 12 and 14. In the eye, it is understood to inhibit carbonic anhydrase II in the ciliary processes, which reduces aqueous humour production and lowers intraocular pressure (IOP). This is established for open-angle glaucoma and ocular hypertension.
Primary hereditary glaucoma is also a disease of raised IOP. A drug that reduces aqueous humour production is therefore mechanistically plausible, and this likely explains the high model score. However, hereditary forms often have structural drainage-angle abnormalities, and the data compiled for this report contain no study of dorzolamide in this setting. The score is a computational association, not clinical proof.
For context, two other predictions in the same analysis, "glaucoma 1, open angle" and "open angle glaucoma", simply confirm the existing approved use. They are supported by Phase 3 and Phase 4 trials and systematic reviews, but they are not new indications.
Clinical Trial Evidence
Currently no related clinical trials registered for primary hereditary glaucoma.
Literature Evidence
Currently no related literature available for primary hereditary glaucoma.
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2398354 (cancelled) | Dortimopt | Eye drops 2% with timolol 0.5% | Not stated in the licence record |
The only New Zealand authorization is a fixed combination with timolol, and it is cancelled. There is currently no valid marketed dorzolamide product in New Zealand. The product is ophthalmic only.
Safety Considerations
- Contraindication-related conditions (from knowledge-graph associations, not label text): diabetes mellitus, diabetic ketoacidosis, myasthenia gravis (including adult-onset), neuromuscular junction disease, hyperthyroidism, Graves disease, thyrotoxicosis, hypoglycaemia, atrioventricular block, pulmonary emphysema, bronchial disease and anaphylaxis. Many of these are typical of beta-blockers, so they may relate to timolol in the combination product rather than to dorzolamide alone. This should be confirmed against the product label.
- Drug interactions: No specific drug-drug interactions were identified. The data list only dorzolamide's pharmacological targets (carbonic anhydrases 1, 7, 12 and 14).
The package insert warnings and contraindications could not be retrieved, so please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score and a plausible IOP-lowering mechanism, but no trial or literature evidence supports it (L5). The only New Zealand licence is cancelled, so there is currently no marketed product.
To proceed, the following is needed:
- Clinical or literature evidence of dorzolamide in primary hereditary (including congenital or juvenile) glaucoma, such as paediatric or genetic-subtype studies
- Mechanism of action data (MOA) to support the mechanistic-link analysis
- The Medsafe package insert warnings and contraindications, to complete safety screening
- Clarification of availability, since the licence is cancelled and the only product is a timolol fixed combination
- Route and formulation compatibility assessment for the proposed use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.